Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate for Attention and Executive Deficits in Children With Sickle Cell Disease
NCT07226219Phase 1Recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Nov 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of methylphenidate hydrochloride extended-release chewable tablet in attention deficit hyperactivity disorder (ADHD) and executive dysfunction, sponsored by St. Jude Children's Research Hospital. Primary endpoints: Feasibility of methylphenidate, Acceptability of methylphenidate at 4 weeks and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
methylphenidate hydrochloride extended-release chewable tablet
03
Conditions
attention deficit hyperactivity disorder (ADHD)executive dysfunction
Beyond the preview
Go deeper on NCT07226219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07226219.